Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair protein

Abstract

In clinical genetic diagnostics, it is difficult to predict whether genetic mutations that do not greatly alter the primary sequence of the encoded protein causing unknown functional effects on cognate proteins lead to development of disease. Here, we report the clinical identification of c.2038 T>C missense mutation in exon 18 of the human MLH1 gene and biochemically characterization of the p.Cys680Arg mutant MLH1 protein to implicate it in the pathogenicity of the Lynch syndrome (LS). We show that the mutation is deficient in DNA mismatch repair and, therefore, contributing to LS in the carriers.

Lynch syndrome (LS) is a multi-tumor syndrome with particularly high risks of colorectal, endometrial, and ovarian cancers. The syndrome is caused by germline DNA mismatch repair (MMR) gene mutations with major contributions from MLH1 (MIM#120436) (42%), MSH2 (MIM#609309) (33%), MSH6 (MIM#600678) (18%), and PMS2 (MIM#600259) (8%) (Plazzer et al. ). Missense variants are estimated to represent one third of the alterations and frequently pose problems in genetic diagnostics related to their functional consequence and possibilities to apply in predictive diagnostics (Peltomaki and Vasen ; Nilbert et al. ; Fan et al. ). While some of these have been defined as disease predisposing, the pathogenic importance of others remains to be defined (Takahashi et al. ; Drost et al. ). Such variants of uncertain significance (VUS) represent a challenge for clinicians and genetic counselors because of their undefined consequences (Heinen and Juel Rasmussen ; Rasmussen et al. ).

We identified a missense mutation MLH1 (NM_000249.3:c.2038 T>C, dbSNP rs63750809) in genetic diagnostics and present evidence for its causality for LS. The individual tested had developed four LS-associated tumors: an endometrial cancer with an ovarian metastasis at age 50; a right-sided colon cancer, T3N0, at age 51; and two synchronous colorectal cancers, a T3N0 cancer of the transverse colon and a T4N0 rectal cancer, at age 67. The family history was limited to a father with a malignant melanoma at age 88. First-step assessment (Data S1) revealed defective MMR, expressed as microsatellite instability (MSI) for the markers BAT-25, MONO-27, NR-21, and NR-24, immunohistochemical loss of MLH1/PMS2, and wild type for BRAF (V600E) mutation in all four tumors (Fig. ). Mutation analysis of MMR genes in lymphocytes identified a missense mutation in MLH1, c.2038 T>C. The variant has been described as pathogenic in silico (Beroud et al. , ; Frederic et al. ; Ali et al. ), and as having unknown effect (Sheng et al. ; Thompson et al. ). The c.2038 T>C alteration leads to a p.Cys680Arg amino acid substitution that is located in the region of MLH1 that is essential for interaction with PMS2 (Guerrette et al. ). In silico analysis was performed using the Polyphen, MAPP-MMR (), SIFT (), and P-mut methods, which predict the impact of mutations on protein function based on evolutionary conservation using sequence-based information (Ferrer-Costa et al. ; Chao et al. ; Kumar et al. ; Adzhubei et al. ; Ali et al. ). All of these models predicted that the variant affects protein function (Table ).

Summary of biochemical, in silico, and functional analysis of the p.Cys680Arg.

Clinical information	Clinical criteria	Amsterdam II
Age at onset	50
Biochemical analysis	Microsatellite instability	MSI high
Immunohistochemical staining	MLH1-/PMS2-
In silico analysis	Polyphen	0.970 (probably damaging)
SIFT	0.02 (not tolerated)
MAPP-MMR	34.150 (affect protein function)
P-mut	0.7897 (pathological)
Functional analysis	Cell-free mismatch repair	Pathogenic
Yeast two-hybrid	No interaction with PMS2

[IMAGE OMITTED. SEE PDF]

The effect of the p.Cys680Arg mutation on MMR function was tested by assessment of its ability to repair a G·T mismatched substrate in a cell-free mismatch repair assay (Drost et al. ) (Fig. A). Protein variants p.Gly67Arg (c.199G>A) and p.Ile219Val (c.655A>G) were included as controls (Drost et al. ). The low repair level observed with the variant p.Gly67Arg reflects its pathogenicity. Variant p.Ile219Val is considered an innocuous polymorphism and showed DNA repair capacity comparable to wild-type MLH1. In this assay, p.Cys680Arg repaired mismatches with an efficiency that was comparable to that of p.Gly67Arg. This strongly supports the pathogenic potential of the p.Cys680Arg variant.

[IMAGE OMITTED. SEE PDF]

The MLH1 protein exists predominately in a complex with PMS2 also known as the MutLα heterodimer (Li and Modrich ). The formation of a MutLα complex is essential for MMR activity (Baker et al. , ; Edelmann et al. ) and, therefore, the failure of LS-MLH1 proteins to associate with PMS2 could result in inefficient MMR. We show in a yeast two-hybrid assay that the MLH1 p.Cys680Arg variant does not interact with PMS2 suggesting that the MMR-deficiency is caused by failure to form the essential MutLα complex (Fig. B).

Summary

The MLH1 c.2038 T>C mutation, which causes the amino acid substitution p.Cys680Arg, was identified in an individual with four synchronous and metachronous tumors, all of which showed a MSI-high phenotype and loss of MLH1/PMS2 expression. The mutation occurs in a region of the MLH1 gene that is involved in MLH1-PMS2 interaction. In silico analysis unanimously suggested a deleterious effect of this mutation, which was confirmed by functional assays. We conclude that since the mutation is deficient in MMR it contributes to LS.

Conflict of Interest

None declared.

References

Adzhubei, I. A., S. Schmidt, L. Peshkin, V. E. Ramensky, A. Gerasimova, P. Bork, et al. 2010. A method and server for predicting damaging missense mutations. Nat. Methods 7:248–249.

Ali, H., A. Olatubosun, and M. Vihinen. 2012. Classification of mismatch repair gene missense variants with PON‐MMR. Hum. Mutat. 33:642–650.

Baker, S. M., C. E. Bronner, L. Zhang, A. W. Plug, M. Robatzek, G. Warren, et al. 1995. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell 82:309–319.

Baker, S. M., A. W. Plug, T. A. Prolla, C. E. Bronner, A. C. Harris, X. Yao, et al. 1996. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat. Genet. 13:336–342.

Beroud, C., G. Collod‐Beroud, C. Boileau, T. Soussi, and C. Junien. 2000. UMD (Universal mutation database): a generic software to build and analyze locus‐specific databases. Hum. Mutat. 15:86–94.

Beroud, C., D. Hamroun, G. Collod‐Beroud, C. Boileau, T. Soussi, and M. Claustres. 2005. UMD (Universal mutation database): 2005 update. Hum. Mutat. 26:184–191.

Chao, E. C., J. L. Velasquez, M. S. Witherspoon, L. S. Rozek, D. Peel, P. Ng, et al. 2008. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms‐mismatch repair (MAPP‐MMR). Hum. Mutat. 29:852–860.

Drost, M., J. Zonneveld, L. van Dijk, H. Morreau, C. M. Tops, H. F. Vasen, et al. 2010. A cell‐free assay for the functional analysis of variants of the mismatch repair protein MLH1. Hum. Mutat. 31:247–253.

Edelmann, W., P. E. Cohen, M. Kane, K. Lau, B. Morrow, S. Bennett, et al. 1996. Meiotic pachytene arrest in MLH1‐deficient mice. Cell 85:1125–1134.

Fan, Y., J. Chen, W. Wang, P. Wu, W. Zhi, B. Xue, et al. 2012. Influence of eight unclassified missense variants of the MLH1 gene on Lynch syndrome susceptibility. Biochem. Genet. 50:84–93.

Ferrer‐Costa, C., M. Orozco, and X. de la Cruz. 2004. Sequence‐based prediction of pathological mutations. Proteins 57:811–819.

Frederic, M. Y., M. Lalande, C. Boileau, D. Hamroun, M. Claustres, C. Beroud, et al. 2009. UMD‐predictor, a new prediction tool for nucleotide substitution pathogenicity – application to four genes: FBN1, FBN2, TGFBR1, and TGFBR2. Hum. Mutat. 30:952–959.

Guerrette, S., S. Acharya, and R. Fishel. 1999. The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer. J. Biol. Chem. 274:6336–6341.

Heinen, C. D., and L. Juel Rasmussen. 2012. Determining the functional significance of mismatch repair gene missense variants using biochemical and cellular assays. Hered. Cancer Clin. Pract. 10:9.

Kumar, P., S. Henikoff, and P. C. Ng. 2009. Predicting the effects of coding non‐synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4:1073–1081.

Li, G. M., and P. Modrich. 1995. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc. Natl. Acad. Sci. USA 92:1950–1954.

Nilbert, M., F. P. Wikman, T. V. Hansen, H. B. Krarup, T. F. Orntoft, F. C. Nielsen, et al. 2009. Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. Fam. Cancer 8:75–83.

Peltomaki, P., and H. Vasen. 2004. Mutations associated with HNPCC predisposition – Update of ICG‐HNPCC/INSiGHT mutation database. Dis. Markers 20:269–276.

Plazzer, J. P., R. H. Sijmons, M. O. Woods, P. Peltomaki, B. Thompson, J. T. Den Dunnen, et al. 2013. The InSiGHT database: utilizing 100 years of insights into Lynch Syndrome. Fam. Cancer

Rasmussen, L. J., C. D. Heinen, B. Royer‐Pokora, M. Drost, S. Tavtigian, R. M. Hofstra, et al. 2012. Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future. Hum. Mutat. 33:1617–1625.

Sheng, J. Q., L. Fu, Z. Q. Sun, J. S. Huang, M. Han, H. Mu, et al. 2008. Mismatch repair gene mutations in Chinese HNPCC patients. Cytogenet Genome Res. 122:22–27.

Takahashi, M., H. Shimodaira, C. Andreutti‐Zaugg, R. Iggo, R. D. Kolodner, and C. Ishioka. 2007. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res. 67:4595–4604.

Thompson, B. A., M. S. Greenblatt, M. P. Vallee, J. C. Herkert, C. Tessereau, E. L. Young, et al. 2013. Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum. Mutat. 34:255–265. doi:10.1002/humu.22214